Frequency Therapeutics Inc Stock
Frequency Therapeutics Inc Stock price
Key metrics
| Market capitalization | $487.15m |
| Enterprise Value | $390.17m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| P/B ratio (TTM) P/B ratio | 2.70 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-108.40m |
| Free Cash Flow (TTM) Free Cash Flow | $-116.69m |
| Cash position | $138.77m |
Is Frequency Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
Frequency Therapeutics Inc Stock Analysis
Analyst Opinions
7 Analysts have issued a Frequency Therapeutics Inc forecast:
Analyst Opinions
7 Analysts have issued a Frequency Therapeutics Inc forecast:
Financial data from Frequency Therapeutics Inc
| Sep '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | -4.06 -4.06 |
20%
20%
|
|
| EBITDA | -104 -104 |
94%
94%
|
EBIT (Operating Income) EBIT | -108 -108 |
84%
84%
|
| Net Profit | -102 -102 |
71%
71%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Frequency Therapeutics Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Frequency Therapeutics, Inc. engages in the development of small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Its product pipeline include Sensorineural hearing loss (FX-322), and Multiple Sclerosis. The company was founded by Robert S. Langer, Jr., David L. Lucchino, Christopher Loose and Will J. McLean on November 13, 2014 and is headquartered in Woburn, MA.
| Head office | United States |
| CEO | Ram Aiyar |
| Employees | 101 |
| Founded | 2018 |
| Website | www.korrobio.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
